Part: 12         Session: 145678910111213141516171819202122         Page 861862863864865866867868869870871872873874875876877878879880881882883884885886887888889890891892893894895896897898899900901902903904905906907908909910911912913914915916917918919920921922923924925926927928929930 of 999

is a small grove of problems, not problems but possible therapies.

This is a very new discovery, isn't it?

It opens up something more complex than we thought, and it's a new discovery. It was discovered within the last year.

I know you didn't talk about that last year.

No, we didn't know it. I found out that there were more than one sub-types of leukocyte interferon last year in Cambridge, England.

Well, so Jordan and I decided that as a big development in what's called mono-clonal antibodies, a discovery of a man called Milstein of Cambridge, England. This had caught on like wildfire in the United States.

Had he been over at that Houston conference?

No, we went there, but it's in the literature, and all young scientists know about mono-clonal antibodies now, and anybody who doesn't know about them is like Osler in the 19th Century ago as that in people's minds, you see. They're out of date.

So we found that there was a group at Yale that was interested in mono-clonal antibodies, and we have a request